Data From AVI BioPharma's RNA-Based Influenza and Dengue Virus Programs to Be Presented at 48th Annual Meeting of Infectious Dis
October 20 2010 - 8:30AM
Marketwired
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based
therapeutics, today announced the presentation of data from the
Company's influenza and dengue virus programs at the 48th Annual
Meeting of the Infectious Diseases Society of America in Vancouver,
Canada.
Patrick Iversen, Ph.D., Senior Vice President of Research and
Innovation at AVI, will present during the poster session,
Virology: Influenza, at noon PDT on Friday, Oct. 22. The
presentation, 766, is titled "PMOplus™ Chemistry for Rapid Response
to Novel Therapeutic for Pandemic Influenza (H1N1-SOIV)." The
presentation will feature preclinical data that identifies AVI-7100
as a lead candidate with a broad safety margin and demonstrated
efficacy in mouse and ferret influenza models challenged by H3N2
and H1N1, respectively.
Dr. Iversen will also present an abstract during the
late-breaking poster session at 12:30 p.m. PDT on Saturday, Oct.
23. The presentation, LB-1, is titled "An Emerging Therapeutic for
the Treatment of Dengue Viral Infections." The presentation will
feature data from preclinical studies of AVI-6006 in dengue virus
infected mouse and ferret models.
Both presentations will be posted on the AVI BioPharma Web site
in the "Our Programs" section after their respective sessions are
completed.
AVI-7100 and AVI-6006 are AVI's lead therapeutic candidates for
influenza and dengue virus infections, respectively. Both
candidates employ AVI's patented PMOplus™ technology that
selectively introduces positive charges to its phosphorodiamidate
morpholino oligomer (PMO) backbone to improve interaction between
the drug and its target.
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of
novel RNA-based therapeutics for rare and infectious diseases, as
well as other select disease targets. Applying pioneering
technologies developed and optimized by AVI, the Company is able to
target a broad range of diseases and disorders through distinct
RNA-based mechanisms of action. Unlike other RNA-based approaches,
AVI's technologies can be used to directly target both messenger
RNA (mRNA) and precursor messenger RNA (pre-mRNA) to either
down-regulate (inhibit) or up-regulate (promote) the expression of
targeted genes or proteins. By leveraging our highly differentiated
RNA antisense-based technology platform, AVI has built a pipeline
of potentially transformative therapeutic agents, including one in
the clinical development stage for the treatment of Duchenne
muscular dystrophy. For more information, visit www.avibio.com.
Forward-Looking Statements and
Information
This press release contains statements that are forward-looking,
including statements about the development of AVI 7100 and 6006,
other antisense-based technology and the efficacy, potency and
utility of our product candidates in the treatment of rare and
infectious diseases, and its potential to treat a broad number of
human diseases. These forward-looking statements involve risks and
uncertainties, many of which are beyond AVI's control. Known risk
factors include, among others: clinical trials may not demonstrate
safety and efficacy of any of AVI's drug candidates and/or AVI's
antisense-based technology platform; any of AVI's drug candidates
may fail in development, may not receive required regulatory
approvals, or be delayed to a point where they do not become
commercially viable. Any of the foregoing risks could materially
and adversely affect AVI's business, results of operations and the
trading price of its common stock. For a detailed description of
risks and uncertainties AVI faces, you are encouraged to review the
official corporate documents filed with filed with the Securities
and Exchange Commission. AVI does not undertake any obligation to
publicly update its forward-looking statements based on events or
circumstances after the date hereof.
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From May 2024 to Jun 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2023 to Jun 2024